ClinicalTrials.gov
ClinicalTrials.gov Menu

Pulse Wave Analysis in Advanced Heart Failure (PWA-HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01642927
Recruitment Status : Withdrawn (PI left University)
First Posted : July 17, 2012
Last Update Posted : January 23, 2017
Sponsor:
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute

Brief Summary:
A comparison of pulse wave characteristics, as measured by peripheral tonometry, in pre and post Left Ventricular Assist Device (LVAD) patients.

Condition or disease
Left Ventricular Assist Device Heart Failure Intra-aortic Balloon Pump LVAD Clot LVAD-related GI Bleed

Detailed Description:

Pulse waveforms, especially central pressure waveforms, are predictive of cardiovascular events. Peripheral waveforms have been correlated to central waveforms. Peripheral waveforms can be easily measured through applanation tonometry. In this study the investigators hypothesize:

  1. That previously established peripheral tonometry techniques would apply to patients with advanced heart failure, including continuous flow LVADs and facilitate serial evaluation of central hemodynamics without invasive monitoring.
  2. That temporary changes in LVAD speed will be evident in frequency spectrum analysis of peripheral, non-invasive waveforms.
  3. That clinical events involving LVAD will have characteristic frequency spectra.

Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Pulse Wave Analysis in Advanced Heart Failure Patients Before and After Ventricular Assist Device
Actual Study Start Date : February 2012
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Group/Cohort
Intra-Aortic Balloon Pump (IABP) Group
Advanced Heart Failure and/or pre-LVAD surgical patient with IABP
IABP/LVAD Group
Post-LVAD surgical patients with IABP
Post-LVAD Group
LVAD patients 3 months or greater post-implantation undergoing echocardiography
LVAD Event Group
LVAD patients who have developed LVAD thrombosis or GI hemorrhage related to LVAD
Arrhythmia group
LVAD patient with an irregular heartbeat.
Valvular disease group
LVAD patient with valvular heart disease
Normal control group
Healthy participant without any known heart disease (Control group).



Primary Outcome Measures :
  1. Observation of pulse wave signatures in LVAD patients [ Time Frame: ongoing ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Advanced heart failure patients, eligible for or currently treated with LVAD, outpatient cardiology clinic or inpatient heart failure service patients
Criteria

Inclusion Criteria:

1)18 years of age or older

2)Advanced heart failure as defined by need for IABP or LVAD

3)One or more of the following:

  • Current inpatient heart failure treatment with intra-aortic balloon pump (IABP)-IABP Group

    •≤ 1 week post-LVAD implantation with current IABP support-IABP/LVAD Group

    •≥ 3 mo post-LVAD placement and scheduled for LVAD speed optimization with echocardiography.-Post-LVAD Group

  • Post-LVAD placement with suspected GI hemorrhage or LVAD thrombosis-LVAD Event Group

    4)Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

Exclusion Criteria:

  1. Clinical status will not permit pause of IABP (IABP and IABP/LVAD Groups)
  2. Unable to undergo echo or oversewn or patched aortic valve (Post-LVAD Group)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642927


Locations
United States, Minnesota
Univeristy of Minnesota Lillehei Heart Institute
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Investigators
Principal Investigator: Peter Eckman, MD University of Minnesota - Clinical and Translational Science Institute

Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT01642927     History of Changes
Other Study ID Numbers: University_of_Minnesota
First Posted: July 17, 2012    Key Record Dates
Last Update Posted: January 23, 2017
Last Verified: January 2017

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
LVAD
IABP
Heart Failure
Thrombosis
Hemorrhage

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases